A population of improved tumor infiltrating lymphocytes (TILs). These TILs have increased metabolic activity (MA), and increased therapeutic efficacy for cancer treatment, allowing applying reduced cell doses to a subject in need thereof. Further disclosed are methods for selecting a population of TILs with increased metabolic activity, methods for producing, and methods for using said TILs.
The disclosure relates to a composition comprising a ribonuclease and a lipid nanoparticle, wherein the ribonuclease local concentration within the lipid nanoparticles is above 1mg/ml. The disclosure further relates to the use of such composition.
C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
3.
SYSTEM AND METHOD FOR ULTRAFILTRATION AND CONCENTRATION OF BIOLOGICAL COMPONENTS WITHIN A LIQUID SUSPENSION
There is provided a method of concentrating functional biological components within a liquid suspension, the method comprising: providing a system comprising an ultrafiltration/concentration unit (UCU), the UCU comprising a first chamber for receiving therein the liquid suspension. a second chamber for receiving therein the filtrate, and a filter disposed in a fluid path therebetween. the filter comprising pores sizes so as to prevent passage therethrough of the biological components: introducing the liquid suspension into the first chamber: maintaining a pressure in the first chamber being no greater than approximately 2 bar; maintaining a pressure in the second chamber being lower than that of the first chamber: and harvesting the concentrated biological components: wherein a retentate is obtained in which the concentration of the biological components therewithin is increased. relative to the liquid suspension. by a factor of at least fifty. and wherein a majority of the biological components in the retentate are functional.
A sterile bio-processing system for cell culturing, the system comprising at least two closed sterile elements, configured to contain fluid, wherein: each of the elements comprises at least one sterile tube, configured for fluid communication; and all of said sterile tubes are made of the same material, adapted to be welded one to another, to allow fluid communication between the different sterile elements of the system; and thereby enable the system to be a closed sterile system.
The present disclosure provides methods of treating cancer using complementary transgenic oncolytic viruses and genetically engineered CAR T cells. In one embodiment, the oncolytic virus comprises nucleotide sequences encoding CD19, or CD19 and IL-12, and the genetically engineered T cells express a chimeric antigen receptor that recognizes CD19.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
6.
CHIMERIC ANTIGEN RECEPTOR WITH MODIFIED HINGE AND TRANSMEMBRANE DOMAIN AND USES THEREOF
The present disclosure provides a chimeric antigen receptor (CAR) molecule comprising a modified hinge and transmembrane domain (HTM-1), wherein the modified hinge and transmembrane domain comprises the amino acid sequence of SEQ ID NO:2. Cells expressing CAR with the modified HTM-1 domain disclosed herein are expected to have enhanced anti-tumor activities with reduced release of pro-inflammatory cytokines.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
7.
COMPOSITIONS COMPRISING TOPIRAMATE FOR TREATING DERMATOLOGICAL CONDITIONS
Disclosed herein are compositions comprising topiramate and bioxome, redoxome, HA, extracellular vesicles (EV), or PRP extracellular vesicles, or any combination thereof. Further provided herein are methods for treating dermatological conditions, and methods for testing said compositions.
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A bioreactor is provided, comprising a housing extending along a vertical axis and defining an internal cavity therewithin, top and bottom covers at opposite ends of the housing, and a plurality of ports, each configured to facilitate fluid communication between the internal cavity and the exterior of the bioreactor. The internal cavity has a frustoconical shape, the frustoconical shape being formed such that horizontal cross-sections are coaxial about a line which is angled with respect to the vertical axis.
This disclosure is directed to new pharmaceutical compositions comprising ranpimase and a polyol, said compositions comprise increased stability. Further disclosed are methods for treating a viral disease by administering said compositions.
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliques; Leurs sels ou anhydrides
A61K 47/14 - Esters d’acides carboxyliques, p.ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/18 - Amines; Amides; Urées; Composés d’ammonium quaternaire; Acides aminés; Oligopeptides ayant jusqu’à cinq acides aminés
A61K 47/20 - Composés organiques, p.ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p.ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes ; Huiles, graisses ou cires naturelles ou naturelles modifiées, p.ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceuticals for the treatment of cancer, infectious diseases, auto-immune diseases, metabolic disorders, dermatological diseases and disorders, musculoskeletal disorders
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceuticals for the treatment of cancer, infectious diseases, auto-immune diseases, metabolic disorders, dermatological diseases and disorders, musculoskeletal disorders;
12.
CHIMERIC ANTIGEN RECEPTOR WITH MODIFIED HINGE AND TRANSMEMBRANE DOMAIN AND USES THEREOF
The present disclosure provides a chimeric antigen receptor (CAR) molecule comprising a modified hinge and transmembrane domain (HTM-1), wherein the modified hinge and transmembrane domain comprises the amino acid sequence of SEQ ID NO:2. Cells expressing CAR with the modified HTM-1 domain disclosed herein are expected to have enhanced anti-tumor activities with reduced release of pro-inflammatory cytokines.
Described herein are hydrogel compositions comprising hyaluronic acid or a pharmaceutically acceptable salt thereof, hydroxypropyl methyl cellulose and a plurality of mesenchymal stromal cells. Additionally described herein are compositions for treatment, and methods for treatment of a disease, comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising hyaluronic acid oorr aa pharmaceutically acceptable salt thereof, hydroxypropyl methyl cellulose and a plurality of mesenchymal stromal cells.
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
A61K 38/39 - Peptides du tissu connectif, p.ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid [CIG]
The present disclosure provides a chimeric antigen receptor (CAR) molecule comprising a modified hinge domain, wherein the hinge domain comprises the amino acid sequence of SEQ ID NO:1. Cells expressing a CAR comprising the modified hinge domain disclosed herein are shown to have enhanced anti-tumor activities with reduced release of pro-inflammatory cytokines.
Disclosed herein is an autologous composition comprising mesenchymal stem stromal cells, wherein the mesenchymal stem stromal cells are derived from adipose tissue collected by punch biopsy from a subject, and the use for the treatment of a disease, including a disease with arthritic lesion progression.
Provided herein are methods for treating cancer comprising intranasal administration of an oncolytic virus or an oncolytic virus-based vector, comprised in a mesenchymal stem cell (MSC), an MSC-derived EV, or in an MSC-derived bioxome. Further, the MSCs, MSC-derived EVs, or MSC-derived bioxomes disclosed herein may be used for treating a central nervous system (CNS) related disorder.
Disclosed herein are multi-antigenic autologous, cell-based SARS-CoV-2 vaccines comprising autologous antigen presenting cells (APCs) displaying at least two different SARS-CoV-2 antigens. These vaccines can be used to prevent SARS-CoV-2 infection or COVID-19. Further disclosed are methods for producing and using the vaccines.
This disclosure is directed to compounds and pharmaceutical compositions for treating and preventing viral diseases, as Covid-19. Among others, the invention relates to the use of ribonucleases and bioxoms, exosomes or combination thereof in the preparations and use of pharmaceutical formulations for the treatment of said disease. In addition, the invention relates to the use of immune cells and ribonucleases in the preparation and use of pharmaceutical formulations for the treatment of said disease.
A cell-culture bioreactor operative to provide real-time reactor management in the fields of stir control, sparge control, and heat management responsively to wireless sensor feedback to optimize operating conditions to maximize cell-culture yield; and a bioreactor comprising: a vessel, having an open top; a headplate, configured to seal the vessel's open top; and a stirring device, comprising at least two independent stirring elements; wherein each of the stirring elements is configured to independently stir media accommodated within the vessel.
Process and system for acellular therapy in a human subject are provided. The process and system relate to an acellular therapy using therapeutic extracellular vehicles fused to biological material obtained from the subject, via transfusion by extracorporeal systems. The process for acellular therapy is in a subject in need of such therapy.
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
A61M 1/02 - Appareils pour transfusion sanguine d'un corps à un autre
A61M 1/34 - Filtration du sang à travers une membrane pour en éliminer une matière, c. à d. hémofiltration, diafiltration
21.
SYSTEM AND METHOD FOR ULTRAFILTRATION AND CONCENTRATION OF BIOLOGICAL COMPONENTS WITHIN A LIQUID SUSPENSION
There is provided a method of concentrating functional biological components within a liquid suspension, the method comprising: providing a system comprising an ultrafiltration/concentration unit (UCU), the UCU comprising a first chamber for receiving therein the liquid suspension, a second chamber for receiving therein the filtrate, and a filter disposed in a fluid path therebetween, the filter comprising pores sizes so as to prevent passage therethrough of the biological components; introducing the liquid suspension into the first chamber; maintaining a pressure in the first chamber being no greater than approximately 2 bar; maintaining a pressure in the second chamber being lower than that of the first chamber; and harvesting the concentrated biological components; wherein a retentate is obtained in which the concentration of the biological components therewithin is increased, relative to the liquid suspension, by a factor of at least fifty, and wherein a majority of the biological components in the retentate are functional.
A population of improved tumor infiltrating lymphocytes (TILs). These TILs have increased metabolic activity (MA), and increased therapeutic efficacy for cancer treatment, allowing applying reduced cell doses to a subject in need thereof. Further disclosed are methods for selecting a population of TILs with increased metabolic activity, methods for producing, and methods for using said TILs.
C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
A bioreactor is provided, comprising a housing extending along a vertical axis and defining an internal cavity therewithin, top and bottom covers at opposite ends of the housing, and a plurality of ports, each configured to facilitate fluid communication between the internal cavity and the exterior of the bioreactor. The internal cavity has a frustoconical shape, the frustoconical shape being formed such that horizontal cross-sections are coaxial about a line which is angled with respect to the vertical axis.
Disclosed herein are compositions comprising topiramate and bioxome, redoxome, HA, extracellular vesicles (EV), or PRP extracellular vesicles, or any combination thereof. Further provided herein are methods for treating dermatological conditions, and methods for testing said compositions.
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
A mobile processing laboratory (MPL) is provided, configured for facilitating performing therewithin a cell therapy process. The MPL comprises a portable enclosure; one or more pieces of laboratory equipment for carrying out the cell therapy process and being housed within the enclosure; a plurality of sensors, each configured to measure information regarding the environment, cellular material of the process, and/or one of the pieces of laboratory equipment; and a computer system configured for management of the cell therapy process. The computer system is configured to facilitate collecting data from the sensors, and to optimize one or more activities associated with performance of the cell therapy process based on data collected from one or more other MPLs configured for performing therewithin substantially the same cell therapy process.
B65G 43/10 - Commande en série des transporteurs fonctionnant en combinaison
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p.ex. par des compteurs de colonies
C12Q 3/00 - Procédés de commande sensible aux conditions du milieu
F24F 3/16 - Systèmes de conditionnement d'air dans lesquels l'air conditionné primaire est fourni par une ou plusieurs stations centrales aux blocs de distribution situés dans les pièces ou enceintes, blocs dans lesquels il peut subir un traitement secondaire; Appareillage spécialement conçu pour de tels systèmes caractérisés par le traitement de l'air autrement que par chauffage et refroidissement par ozonisation
F24F 8/15 - Traitement, p.ex. purification, de l'air fourni aux locaux de résidence ou de travail des êtres humains autrement que par chauffage, refroidissement, humidification ou séchage par séparation, p.ex. par filtrage par des moyens chimiques
G06Q 10/06 - Ressources, gestion de tâches, des ressources humaines ou de projets; Planification d’entreprise ou d’organisation; Modélisation d’entreprise ou d’organisation
This disclosure is directed to new pharmaceutical compositions comprising ranpirnase and a polyol, said compositions comprise increased stability. Further disclosed are methods for treating a viral disease by administering said compositions.
This disclosure is directed to compounds and pharmaceutical compositions for treating and preventing viral diseases, as Covid-19. Among others, the invention relates to the use of ranpirnase in the preparation and use of pharmaceutical formulations for the intravenous treatment of said disease.
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir d
This disclosure is directed to compounds and pharmaceutical compositions for treating and preventing viral diseases, as Covid-19. Among others, the invention relates to the use of ribonucleases and bioxoms, exosomes or combination thereof in the preparations and use of pharmaceutical formulations for the treatment of said disease. In addition, the invention relates to the use of immune cells and ribonucleases in the preparation and use of pharmaceutical formulations for the treatment of said disease.
A61K 47/42 - Protéines; Polypeptides; Leurs produits de dégradation; Leurs dérivés p.ex. albumine, gélatine ou zéine
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61P 31/20 - Antiviraux pour le traitement des virus ADN
A61P 31/22 - Antiviraux pour le traitement des virus ADN des virus de l'herpès
This disclosure is directed to compounds and pharmaceutical compositions for treating and preventing viral diseases, as Covid-19. Among others, the invention relates to the use of immune cells and ribonucleases in the preparation and use of pharmaceutical formulations for the treatment of said disease.
A cell-culture bioreactor operative to provide real-time reactor management in the fields of stir control, sparge control, and heat management responsively to wireless sensor feedback to optimize operating conditions to maximize cell-culture yield; and a bioreactor comprising: a vessel, having an open top; a headplate, configured to seal the vessel's open top; and a stirring device, comprising at least two independent stirring elements; wherein each of the stirring elements is configured to independently stir media accommodated within the vessel.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
Process and system for acellular therapy in a human subject are provided. The process and system relate to an acellular therapy using therapeutic extracellular vehicles fused to biological material obtained from the subject, via transfusion by extracorporeal systems. The process for acellular therapy is in a subject in need of such therapy.
A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
A61M 1/02 - Appareils pour transfusion sanguine d'un corps à un autre
A61K 47/00 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceuticals for the treatment of cancer, infectious diseases, auto-immune diseases, metabolic disorders, dermatological diseases and disorders, musculoskeletal disorders. Pharmaceutical drug development services; pharmaceutical products development; pharmaceutical research and development; development of cell therapy products; customization of third-party technologies in the nature of scientific apparatus for processing cells for the manufacture and processing of cells to be used as part of advance cell therapies; development of technologies for the manufacture and processing of cells to be used as part of advance cell therapies.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceuticals for the treatment of cancer, infectious diseases, auto-immune diseases, metabolic disorders, dermatological diseases and disorders, musculoskeletal disorders. Pharmaceutical drug development services; pharmaceutical products development; pharmaceutical research and development; development of cell therapy products; customization of third-party technologies in the nature of scientific apparatus for processing cells for the manufacture and processing of cells to be used as part of advance cell therapies; development of technologies for the manufacture and processing of cells to be used as part of advance cell therapies.
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical drug development services; pharmaceutical products development; pharmaceutical research and development; development of cell therapy products; customization of third-party technologies in the nature of scientific apparatus for processing cells for the manufacture and processing of cells to be used as part of advance cell therapies; development of technologies for the manufacture and processing of cells to be used as part of advance cell therapies
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical drug development services; pharmaceutical products development; pharmaceutical research and development; development of cell therapy products; customization of third-party technologies in the nature of scientific apparatus for processing cells for the manufacture and processing of cells to be used as part of advance cell therapies; development of technologies for the manufacture and processing of cells to be used as part of advance cell therapies
The present disclosure provides methods for prophylactically treating a subject for viral infections comprising topically administering a ranpirnase composition. The disclosure also provides compositions that could be used for prophylactic treatment.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
Provided an artificial bioxome particle comprising a cell membrane component and designed to undergo fusion with a target cell, wherein said bioxome particle is engineered to carry a cargo comprising at least one predetermined active molecule; and wherein said cargo can be released into the target cell after the fusion of the bioxome particle with the target cell; and wherein the cell membrane component is derived from a selected cellular or extracellular source; methods of use of the particles; and processes for manufacturing thereof.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 31/00 - Agents anti-infectieux, c. à d. antibiotiques, antiseptiques, chimiothérapeutiques
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
41.
THREE DIMENSIONAL CLUSTERS OF TRANSDIFFERENTIATED CELLS, COMPOSITIONS AND METHODS THEREOF
B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (Israël)
Inventeur(s)
Assa Kunik, Efrat
Cohen, Smadar
Monsonego, Alon
Abrégé
The present disclosure provides compositions and methods for providing a cell replacement therapy to treat various diseases, including pancreatic diseases and diabetes. Specifically, the disclosure provides three-dimensional (3D) cell clusters of transdifferentiated insulin producing cells attached to scaffolds, such as a polysaccharide matrix, in order to provide a cell replacement therapy.
A61K 35/39 - Appareil digestif Îlots de Langerhans
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
A61P 5/48 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques
A61P 5/50 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques pour augmenter ou potentialiser l'activité de l'insuline
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
Viral infections of the eye, and particularly viral infections in the Herpesviridae and Adenoviridae families, can be treated by administration of a pharmaceutical made up of an enzymatically active ribonuclease and a vehicle. Advantageously, the enzymatically active ribonuclease is ranpirnase, the '805 variant, rAmphinase 2, and Amphinase 2, and the vehicle is an aqueous solution.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
cell therapy products, namely, pancreatic islet cell preparations for the treatment of pancreatic diseases research and development services in the field of cell therapies cell therapy services for the treatment of pancreatic diseases; administration of cell therapy services for the treatment of pancreatic diseases
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
cell therapy products, namely, pancreatic islet cell preparations for the treatment of pancreatic diseases research and development services in the field of cell therapies cell therapy services for the treatment of pancreatic diseases; administration of cell therapy services for the treatment of pancreatic diseases
09 - Appareils et instruments scientifiques et électriques
Produits et services
Automated cell extraction systems, namely, electronic apparatus for cell separation for scientific and research use, electrophysiological measurement, growth and testing of cells; electronic apparatus for cell separation; electronic apparatus for low pressure vascular graft sodding
An experiment has shown that ranpirnase is a microbicide. It is believed that topical application of a topical pharmaceutical composition consisting essentially of a prophylactically effective concentration of an enzymatically-active ribonuclease (e.g. ranpirnase) and a viscous vehicle that does not unacceptably interfere with the enzymatic activity (e.g. K-Y® Brand Jelly) will prophylactically protect an individual from a sexually-transmitted viral infection, particularly HIV. It is also believed that e.g. ranpirnase can be delivered to tissues of an individual who is to be prophylactically protected against viral infections by transfecting ranpirnase DNA into human microbiota and exposing the individual to the thus-modified human microbiota. It is also believed that ranpirnase can be delivered to a woman who is to be prophylactically protected against a sexually-transmitted viral infection by use of an intravaginal ring that has been impregnated with ranpirnase.
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
50.
PHARMACEUTICALS FOR TREATMENT OF VIRAL INFECTIONS OF THE EYE
Viral infections of the eye, and particularly viral infections in the Herpesviridae and Adenoviridae families, can be treated by administration of a pharmaceutical made up of an enzymatically active ribonuclease and a vehicle. Advantageously, the enzymatically active ribonuclease is ranpirnase, and the vehicle is an aqueous solution.
Viral infections of the eye, and particularly viral infections in the Herpesviridae and Adenoviridae families, can be treated by administration of a pharmaceutical made up of an enzymatically active ribonuclease and a vehicle. Advantageously, the enzymatically active ribonuclease is ranpirnase, the '805 variant, rAmphinase 2, and Amphinase 2, and the vehicle is an aqueous solution.
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
Automated cell extraction systems, namely, electronic apparatus for cell separation for scientific and research use Automated cell extraction systems, namely, electronic apparatus for cell separation for medical use
53.
Antiviral pharmaceutical for topical administration
An enzymatically-active ribonuclease is combined with a vehicle that does not unacceptably interfere with such enzymatic activity and applied externally. Advantageously, the ribonuclease is ranpirnase. The vehicle can be a liquid, a gel, an ointment, or a serum, and can also be an approved sexual lubricant.
Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against rabies, Middle East Respiratory Syndrome Coronavirus (“MERS-CoV”), influenza, Ebola virus, Chikungunya virus, Venezuelan equine encephalitis, canine parvovirus, adenovirus-2, respiratory syncytial virus, rhinovirus-14, and vaccinia are disclosed.
C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
C07K 7/00 - Peptides ayant de 5 à 20 amino-acides dans une séquence entièrement déterminée; Leurs dérivés
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir d
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
55.
RNASE FOR USE IN TREATING OR PREVENTING VIRAL INFECTIONS
Ribonucleases of the RNase A superfamily or a functional derivative thereof are broadly useful for the treatment or prevention of viral infections caused by viruses classified in Baltimore Groups I, II, IV and V in mammalian subjects.
Ribonucleases of the RNase A superfamily or a functional derivative thereof are broadly useful for the treatment or prevention of viral infections caused by viruses classified in Baltimore Groups I, II, IV and V in mammalian subjects.
Three RNases (ranpirnase, the second embodiment disclosed in U.S. Pat. No. 5,728,805, and recombinant Amphinase-2) are tested against identified herpesviridae infections. With some exceptions, quantitative PCR assays indicate that the RNases have anti-viral activity against many of these viruses.
Two RNases (ranpirnase and the second embodiment disclosed in U.S. Pat. No. 5,728,805) are tested against human papillomavirus infections. QRT-PCR assays indicate that the RNases have anti-viral activity against type 11 HPV.
Three RNases (ranpirnase, the second embodiment disclosed in U.S. Pat. No. 5,728,805, and recombinant Amphinase-2) are tested against identified herpesviridae infections. With some exceptions, quantitative PCR assays indicate that the RNases have anti-viral activity against many of these viruses.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Chemicals used in industry and science. Enzyme preparations for medical and veterinary use; enzyme preparations for tissue dissociation; pharmaceutical and veterinary preparations.
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Automated cell extraction and cell culture systems, namely, electronic apparatus for electrophysiological measurement, growth and testing of cells; electronic apparatus for cell separation; electronic apparatus for coating of vascular grafts under low pressure; automated perfusion bioreactors to provide culture replication for point-of-care, operating room, clinical and experimental use; scientific apparatus and instruments. Medical apparatus and instruments. Medical laboratory services, namely, separation, isolation and preparation of therapeutic cells; scientific and technological services and research and design relating thereto.
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Automated cell extraction and cell culture systems, namely, electronic apparatus for electrophysiological measurement, growth and testing of cells; electronic apparatus for cell separation; electronic apparatus for coating vascular grafts under low pressure; automated perfusion bioreactors to provide culture replication for point-of-care, operating room, clinical and experimental use; scientific apparatus and instruments. Medical apparatus and instruments. Medical laboratory services, namely, separation, isolation and preparation of therapeutic cells; scientific and technological services and research and design relating thereto.
